Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only, Manufactured by: Cadila Healthcare ltd., Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-110-06
Published September 14, 2016 · Recall initiated: May 9, 2016
Summary
FDA records drug Class II recall D-1491-2016, published September 14, 2016 and initiated May 9, 2016. Recalling firm: Zydus Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 14,808 bottles; Lot: Lot # MP993, Exp10/16; MR2704, Exp 02/17; MR6851, MR8100; Exp 07/17 and MR1210, Exp 12/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches.
What to do
Voluntary: Firm initiated · Letter
Get an email if BROMOCRIPTINE MESYLATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- BROMOCRIPTINE MESYLATE
- Manufacturer
- Zydus Pharmaceuticals USA Inc
- Distributor
- US Nationwide
- UPC
- 0368382110015
- Lot
- Lot # MP993, Exp10/16; MR2704, Exp 02/17; MR6851, MR8100; Exp 07/17 and MR1210, Exp 12/17
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: ZydusNovember 26, 2025
- FDADextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and AmphetamineSeptember 14, 2016
- FDAARGATROBAN Injection in 0.9% Sodium Chloride 250 mg/250 mL (1 mg/mL) , Rx Only, Manufactured in Hungary forSeptember 14, 2016
- FDADextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and AmphetamineSeptember 14, 2016
- FDALinezolid Injection 600 mg/300 mL Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., NorthSeptember 14, 2016
- FDADextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and AmphetamineSeptember 14, 2016
Questions about this recall
Was Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only, Manufactured by: Cadila Healthcare ltd., Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-110-06 recalled?
Yes. FDA published recall D-1491-2016 on September 14, 2016. Reported hazard: Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: BROMOCRIPTINE MESYLATE. UPC: 0368382110015.